Literature DB >> 21454610

A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.

Sudharshan Eathiraj1, Rocio Palma, Marscha Hirschi, Erika Volckova, Enkeleda Nakuci, Jennifer Castro, Chang-Rung Chen, Thomas C K Chan, Dennis S France, Mark A Ashwell.   

Abstract

Protein kinase inhibitors with enhanced selectivity can be designed by optimizing binding interactions with less conserved inactive conformations because such inhibitors will be less likely to compete with ATP for binding and therefore may be less impacted by high intracellular concentrations of ATP. Analysis of the ATP-binding cleft in a number of inactive protein kinases, particularly in the autoinhibited conformation, led to the identification of a previously undisclosed non-polar region in this cleft. This ATP-incompatible hydrophobic region is distinct from the previously characterized hydrophobic allosteric back pocket, as well as the main pocket. Generalized hypothetical models of inactive kinases were constructed and, for the work described here, we selected the fibroblast growth factor receptor (FGFR) tyrosine kinase family as a case study. Initial optimization of a FGFR2 inhibitor identified from a library of commercial compounds was guided using structural information from the model. We describe the inhibitory characteristics of this compound in biophysical, biochemical, and cell-based assays, and have characterized the binding mode using x-ray crystallographic studies. The results demonstrate, as expected, that these inhibitors prevent activation of the autoinhibited conformation, retain full inhibitory potency in the presence of physiological concentrations of ATP, and have favorable inhibitory activity in cancer cells. Given the widespread regulation of kinases by autoinhibitory mechanisms, the approach described herein provides a new paradigm for the discovery of inhibitors by targeting inactive conformations of protein kinases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454610      PMCID: PMC3121527          DOI: 10.1074/jbc.M110.213736

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.

Authors:  M Mohammadi; G McMahon; L Sun; C Tang; P Hirth; B K Yeh; S R Hubbard; J Schlessinger
Journal:  Science       Date:  1997-05-09       Impact factor: 47.728

2.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery.

Authors:  Mei-Chu Lo; Ann Aulabaugh; Guixian Jin; Rebecca Cowling; Jonathan Bard; Michael Malamas; George Ellestad
Journal:  Anal Biochem       Date:  2004-09-01       Impact factor: 3.365

3.  Allosteric cooperativity in protein kinase A.

Authors:  Larry R Masterson; Alessandro Mascioni; Nathaniel J Traaseth; Susan S Taylor; Gianluigi Veglia
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-04       Impact factor: 11.205

4.  Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states.

Authors:  Irina Kufareva; Ruben Abagyan
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

5.  ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

Authors:  Neru Munshi; Sébastien Jeay; Youzhi Li; Chang-Rung Chen; Dennis S France; Mark A Ashwell; Jason Hill; Magdi M Moussa; David S Leggett; Chiang J Li
Journal:  Mol Cancer Ther       Date:  2010-05-18       Impact factor: 6.261

6.  Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.

Authors:  Tai W Wong; Francis Y Lee; Chiang Yu; Feng R Luo; Simone Oppenheimer; Hongjian Zhang; Richard A Smykla; Harold Mastalerz; Brian E Fink; John T Hunt; Ashvinikumar V Gavai; Gregory D Vite
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

7.  Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening.

Authors:  Krishna P Ravindranathan; Valsan Mandiyan; Anil R Ekkati; Jae H Bae; Joseph Schlessinger; William L Jorgensen
Journal:  J Med Chem       Date:  2010-02-25       Impact factor: 7.446

8.  'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.

Authors:  Antonio Garrido Montalban; Erik Boman; Chau-Dung Chang; Susana Conde Ceide; Russell Dahl; David Dalesandro; Nancy G J Delaet; Eric Erb; Andrew Gibbs; Jeff Kahl; Linda Kessler; Jan Lundström; Stephen Miller; Hiroshi Nakanishi; Ed Roberts; Eddine Saiah; Robert Sullivan; Zhijun Wang; Christopher J Larson
Journal:  Bioorg Med Chem Lett       Date:  2008-09-11       Impact factor: 2.823

9.  An autoinhibitory tyrosine motif in the cell-cycle-regulated Nek7 kinase is released through binding of Nek9.

Authors:  Mark W Richards; Laura O'Regan; Corine Mas-Droux; Joelle M Y Blot; Jack Cheung; Swen Hoelder; Andrew M Fry; Richard Bayliss
Journal:  Mol Cell       Date:  2009-11-25       Impact factor: 17.970

10.  Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2.

Authors:  Baoguang Zhao; Angela Smallwood; Jingsong Yang; Kristin Koretke; Kelvin Nurse; Amy Calamari; Robert B Kirkpatrick; Zhihong Lai
Journal:  Protein Sci       Date:  2008-07-28       Impact factor: 6.725

View more
  13 in total

1.  FGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical Signatures.

Authors:  Tobias Klein; Julie Tucker; Geoffrey A Holdgate; Richard A Norman; Alexander L Breeze
Journal:  ACS Med Chem Lett       Date:  2013-12-06       Impact factor: 4.345

2.  Conformational Control of UDP-Galactopyranose Mutase Inhibition.

Authors:  Kittikhun Wangkanont; Valerie J Winton; Katrina T Forest; Laura L Kiessling
Journal:  Biochemistry       Date:  2017-07-20       Impact factor: 3.162

3.  Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).

Authors:  Yan Li; Michel Delamar; Patricia Busca; Guillaume Prestat; Laurent Le Corre; Laurence Legeai-Mallet; RongJing Hu; Ruisheng Zhang; Florent Barbault
Journal:  J Comput Aided Mol Des       Date:  2015-03-26       Impact factor: 3.686

4.  FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma.

Authors:  Yuanyuan Shi; Xuejiao Liu; Mangaladoss Fredimoses; Mengqiu Song; Hanyong Chen; Kangdong Liu; Mee-Hyun Lee; Zigang Dong
Journal:  J Cell Biochem       Date:  2017-10-27       Impact factor: 4.429

5.  Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.

Authors:  Apurva K Srivastava; Melinda G Hollingshead; Jennifer Weiner; Tony Navas; Yvonne A Evrard; Sonny A Khin; Jiuping Jay Ji; Yiping Zhang; Suzanne Borgel; Thomas D Pfister; Robert J Kinders; Donald P Bottaro; W Marston Linehan; Joseph E Tomaszewski; James H Doroshow; Ralph E Parchment
Journal:  Clin Cancer Res       Date:  2016-03-21       Impact factor: 12.531

6.  Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer.

Authors:  Jianzhang Wu; Tao Wei; Qinqin Tang; Bixia Weng; Wulan Li; Xin Jiang; Ting Ding; Xiaokun Li; Guang Liang; Yuepiao Cai; Jiansong Ji
Journal:  BMC Cancer       Date:  2015-04-12       Impact factor: 4.430

7.  Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.

Authors:  Jianzhang Wu; Jiansong Ji; Bixia Weng; Peihong Qiu; Karvannan Kanchana; Tao Wei; Yi Wang; Yuepiao Cai; Xiaokun Li; Guang Liang
Journal:  Oncotarget       Date:  2014-06-30

Review 8.  Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Int J Mol Sci       Date:  2014-08-08       Impact factor: 5.923

9.  DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.

Authors:  Zhifeng Huang; Li Tan; Huiyan Wang; Yang Liu; Steven Blais; Jingjing Deng; Thomas A Neubert; Nathanael S Gray; Xiaokun Li; Moosa Mohammadi
Journal:  ACS Chem Biol       Date:  2014-10-27       Impact factor: 5.100

10.  Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases.

Authors:  Huaibin Chen; William M Marsiglia; Min-Kyu Cho; Zhifeng Huang; Jingjing Deng; Steven P Blais; Weiming Gai; Shibani Bhattacharya; Thomas A Neubert; Nathaniel J Traaseth; Moosa Mohammadi
Journal:  Elife       Date:  2017-02-06       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.